Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine on Perfusion Index and Microcirculation in Sepsis
NCT03151668Phase 3Unknown
- Sponsor
- Cairo University
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in septic shock and sepsis (2 arms), sponsored by Cairo University. Primary endpoint: Microvascular Flow Index at 6 hours. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on NCT03151668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151668.